A randomized controlled trial for Vitamin A Palmitate Eye Gel in the Graves ophthalmopathy with dry eye syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033874

Enrollment

Unknown

Registered

2020-06-15

Start date

2020-06-14

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves ophthalmopathy

Interventions

One:0.1%Hyaluronic acid sodium eye drops

Two:vitamin A palmitate eye gel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. over 18 years old; 2. Confirmed TAO; 3. Diagnosed dry eye syndrome; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Suffering from other ophthalmic diseases affecting the ocular surface; 2. Suffering SLE, RA, SS and other autoimmune diseases; 3. Previous eye trauma or surgery; 4. DON (orbital imaging examination showed that the enlarged extraocular muscles compressed the orbital optic nerve, and the patient's vision decreased after the onset of the disease); 5. Allergic to the use of drugs.

Design outcomes

Primary

Measure	Time frame
Basal lacrimal secretion;Tear break-up time;Corneal fluorescence staining;	—

Secondary

Measure	Time frame
The amount of goblet cells of conjunctiva;	—

Countries

China

Contacts

Public ContactZhou Huifang

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

fangzzfang@163.com+86 13661901886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026